Adjusted daily closes · 252 observations · as of Nov 9, 2026
Historical data, not a forecast
1 month
+12.0%
3 months
+25.4%
6 months
+28.4%
1 year
+46.0%
Year to date
+40.4%
52-week range
$115.31 – $174.48
Fundamental snapshot
Latest reported period: Sep 30, 2026
Sharadar reported data
Market cap
$207B
P/E
-53.6
P/B
15.9
P/S
6.7
Revenue
$30.99B
Net income
-$3.86B
Diluted EPS
-3.16
Gross margin
79.90%
Net margin
-12.50%
Return on equity
-21.70%
Total debt
$26.23B
Cash
$6.44B
Free cash flow
$13.78B
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Sep 30, 2026
$8.3B
$2.43B
81.10%
29.30%
$4.8B
Jun 30, 2026
$7.8B
-$10.5B
79.80%
-134.50%
$3.43B
Mar 31, 2026
$6.96B
$2.02B
79.20%
29.00%
$2.43B
Dec 31, 2025
$7.93B
$2.18B
79.50%
27.50%
$3.12B
Sep 30, 2025
$7.77B
$3.05B
79.80%
39.30%
$3.96B
Jun 30, 2025
$7.08B
$1.96B
78.80%
27.70%
$720M
Mar 31, 2025
$6.67B
$1.32B
76.90%
19.70%
$1.65B
Dec 31, 2024
$7.57B
$1.78B
79.10%
23.60%
$2.83B
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Gilead Sciences is set to report its third-quarter 2026 earnings on October 29, with analysts expecting $2.21 EPS on $7.81 billion in revenue, indicating a challenging year-over-year earnings comparison despite stable revenue. The consensus EPS has seen a slight upward revision recently, but the overall outlook suggests potential margin compression or increased operating expenses. Investors will focus on gross and operating margin trends, pipeline updates, and management's guidance for future quarters.
Gilead Sciences' $1.275 billion upfront investment in an oral peptide program from PepStar Therapeutics highlights growing big pharma interest in oral peptide therapies, even at early development stages. This puts a spotlight on companies like Entera Bio, which is advancing its oral peptide EB613 for osteoporosis into Phase 3 with promising patient efficacy data and secured funding. The article suggests that Entera's N-Tab platform, designed to enable oral delivery of complex peptides, could unlock broader markets for bone-building treatments and other conditions.